drugset / Trial / NCT06211179

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

NCT06211179

Phase 1 Completed 34 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study to assess the relative bioavailability of 5 mg Mavacamten opened capsule administered via nasogastric tube compared to intact oral 5 mg Mavacamten in healthy volunteers.

Timeline

Start
2024-01-10
Primary completion
2024-06-13
Completion
2024-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavacamten Small molecule 5 mg Oral

Indications

No indication recorded.